Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

Abstract

Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

“…Given the limited therapy choices for the vast majority of patients and the promising results of immune checkpoint inhibitors (ICIs) in other advanced diseases such as melanoma and lung cancer, there is a growing emphasis on treating prostate cancer with ICIs [8,9]. Although immune checkpoint blockade has been shown to be effective in urothelial and renal-cell carcinomas [10,11], prostate cancer has a more immunosuppressive microenvironment than these other genitourinary malignancies, suggesting that mCRPC may be less susceptible to immune checkpoint blockade [12,13].…”

ICIs-Related Cardiotoxicity in Different Types of Cancer

“…In seven studies [ 48 , 49 , 50 , 51 , 52 , 53 , 54 ] comprising 1971 patients with renal cell carcinomas on ICIs, 14 developed CAEs with an incidence of 0.20–2.19% in which grade 3–5 CAEs accounted for 35.7%. Commonly encountered cardiotoxicities included hypertension (85.7%) and myocarditis (7.1%).…”

Demographic Characteristics and Treatment Outcomes of Advanced Renal Cell Carcinoma With Clear Cell Histology: A Single-Center Experience From India

“…Later, cabozantinib, another multikinase inhibitor (including VEGF), showed superior progression-free survival (PFS) and overall response (OS) rates compared to sunitinib in a phase 2 clinical trial in intermediate and poor-risk clear cell mRCC [ 7 ]. Subsequently, immune checkpoint inhibitors (ICIs) showed excellent results in the second-line setting and later moved to first-line treatment with the combination of VEGF TKI, which had a better response rate and durable survival outcome [ 8 , 9 ].…”